**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 72100

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: A retrospective cohort study**

Brisinda G *et al*. Postoperative complications in gastric cancer surgery

Giuseppe Brisinda, Maria Michela Chiarello, Anna Crocco, Neill James Adams, Pietro Fransvea, Serafino Vanella

**Giuseppe Brisinda,** Abdominal Surgery, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00168, Italy

**Giuseppe Brisinda,** Department of Medical and Surgical Sciences, Università Cattolica del Sacro Cuore, Rome 00168, Italy

**Maria Michela Chiarello,** General Surgery Operative Unit, Azienda Sanitaria Provinciale di Crotone, Ospedale San Giovanni di Dio, Crotone 88900, Italy

**Anna Crocco,** Endocrine Surgery Operative Unit, Istituto Nazionale Tumori, IRCCS Fondazione Pascale, Napoli 80100, Italy

**Neill James Adams,** Health Sciences, Clinical Microbiology Unit, Magna Grecia University, Catanzaro 88100, Italy

**Pietro Fransvea,** Department of Emergency Surgery and Trauma Center, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00168, Italy

**Serafino Vanella,** Department of General and Oncological Surgery, Azienda Ospedaliera San Giuseppe Moscati, Avellino 83100, Italy

**Author contributions:** Brisinda G and Chiarello MM designed the research; Brisinda G, Chiarello MM and Vanella S performed the research; Crocco A and Vanella S analyzed the data; Brisinda G, Chiarello MM, Vanella S, Adams NJ and FransveaPwrote the paper.

**Corresponding author: Giuseppe Brisinda, MD,** Fondazione Policlinico Universitario A Gemelli IRCCS, Largo Agostino Gemelli 8, Rome 00168, Italy. gbrisin@tin.it

**Received:** October 4, 2021

**Revised:** November 9, 2021

**Accepted:** January 11, 2022

**Published online:** January 21, 2022

**Abstract**

BACKGROUND

Surgery for gastric cancer is a complex procedure and lymphadenectomy is often mandatory. Postoperative mortality and morbidity after curative gastric cancer surgery is not insignificant.

AIM

To evaluate the factors determining mortality and morbidity in a population of patients undergoing R0 resection and D2 lymphadenectomy for gastric cancer.

METHODS

A retrospective analysis of clinical data and pathological characteristics (age, sex, primary site of the tumor, Lauren histotype, number of positive lymph nodes resected, number of negative lymph nodes resected, and depth of invasion as defined by the standard nomenclature) was conducted in patients with gastric cancer. For each patient we calculated the Kattan’s score. We arbitrarily divided the study population of patients into two groups based on the nomogram score (< 100 points or ≥ 100 points). Prespecified subgroups in these analyses were defined according to age (≤ 65 years or > 65 years), and number of lymph nodes retrieved (≤ 35 lymph nodes or > 35 lymph nodes). Uni- and multivariate analysis of clinical and pathological findings were performed to identify the factors affecting postoperative mortality and morbidity.

RESULTS

One-hundred and eighty-six patients underwent a curative R0 resection with D2 lymphadenectomy. Perioperative mortality rate was 3.8% (7 patients); a higher mortality rate was observed in patients aged > 65 years (*P* =0.002) and in N+ patients (*P* =0.04). Following univariate analysis, mortality was related to a Kattan’s score ≥ 100 points (*P* =0.04) and the presence of advanced gastric cancer (*P* =0.03). Morbidity rate was 21.0% (40 patients). Surgical complications were observed in 17 patients (9.1%). A higher incidence of morbidity was observed in patients where more than 35 lymph nodes were harvested (*P* =0.0005).

CONCLUSION

Mortality and morbidity rate are higher in N+ and advanced gastric cancer patients. The removal of more than 35 lymph nodes does not lead to an increase in mortality.

**Key Words:** Gastric cancer; Total gastrectomy; Subtotal gastrectomy; Lymphadenectomy; Kattan’s nomogram; Mortality; Postoperative complications; Postoperative pancreatic fistula; Hemoperitoneum; Anastomotic leakage

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Brisinda G, Chiarello MM, Crocco A, Adams NJ, Fransvea P, Vanella S. Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: A retrospective cohort study. *World J Gastroenterol* 2022; 28(3): 381-398

**URL:** https://www.wjgnet.com/1007-9327/full/v28/i3/381.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v28.i3.381

**Core Tip:** Surgery for gastric cancer is a complex procedure. The aim of our study is to evaluate the factors determining mortality and morbidity in 186 patients undergoing R0 resection and D2 lymphadenectomy for gastric cancer. Perioperative mortality rate was 3.8%; a higher mortality rate was observed in patients aged > 65 years and in N+ patients. Mortality was related to a Kattan’s score ≥ 100 points and the presence of advanced gastric cancer. Morbidity rate was 21.0%. Surgical complications were observed in 17 patients. A higher incidence of morbidity was observed in patients where more than 35 lymph nodes were harvested.

**INTRODUCTION**

Although the incidence of gastric cancer is steadily declining, the disease remains the second leading cause of cancer death[1,2]. Currently, surgery is the only potentially curative treatment for gastric cancer[3,4]. The depth of primary tumor invasion, lymph node involvement, and distant metastasis are the major predictors of prognosis for patients with gastric cancer[5].

Node metastases occur during the early stages of the disease, and lymphadenectomy is recommended as the main intervention of a radical surgical treatment[4,6,7]. According to the TNM staging system proposed by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC)[8], the N stage is classified into 5 Levels based on the number of metastatic lymph nodes. However, the extent of lymphadenectomy, which aims to achieve the highest optimal outcome, has been a controversial topic for a long time with no worldwide consensus as of yet[9]. A minimum of 16 lymph nodes has been recommended as an adequate number in radical gastrectomy for gastric cancer to ensure reliable N staging. Studies have shown that the number of dissected metastatic lymph nodes influences prognosis[10].

Gastric cancer surgery is a complex procedure; in this context, lymphadenectomy is mandatory[11-14]. Mortality and morbidity after curative gastric cancer surgery are not negligible[15-17]. There are many clinical and pathological factors that induce an increase in mortality and morbidity[18]. The extent of the lymphadenectomy is one of these factors. The development of postoperative complications, and the associated mortality, is also influenced by the stage of the disease, the number of lymph node metastases, the removal of contiguous organs and the age of the patient.

In this paper, we evaluated patients with histologically confirmed gastric adenocarcinoma, who underwent curative gastrectomy and D2 lymphadenectomy according to the Japanese Gastric Cancer Association (JGCA) guidelines[19,20]. The primary endpoint of the study is to evaluate the factors determining mortality and morbidity in a population of patients undergoing R0 resection and D2 lymphadenectomy for gastric cancer. For each patient we calculated the Kattan’s score. In agreement with the original report by Kattan *et al*[21] the following prognostic variables were assembled for use in validating the nomogram: age, sex, primary site [distal one-third, middle one-third, proximal one-third, and gastroesophageal junction (GEJ)], Lauren histotype (diffuse, intestinal, mixed), number of positive lymph nodes resected, number of negative lymph nodes resected and depth of invasion as defined by the standard nomenclature. We arbitrarily divided the study population of patients into two groups based on the nomogram score (< 100 points or ≥ 100 points). Prespecified subgroups in these analyses were defined according to age (≤ 65 years or > 65 years) and number of lymph nodes retrieved (≤ 35 lymph nodes or > 35 lymph nodes). The cut off was used in this study since age > 65 years is considered a significant risk factor for postoperative complications in gastric surgery, and was also in accordance with a definition of age limits for elderly patients. Clinical factors and pathological findings were evaluated to identify the factors that induce increased postoperative mortality and morbidity in patients undergoing R0 surgery. Treatment factors were also analyzed for their impact on mortality and morbidity.

**MATERIALS AND METHODS**

This is a retrospective study. An analysis of clinical data and pathological characteristics was conducted on patients with gastric cancer observed and treated at the General Surgery Operative Unit, Fondazione Policlinico Universitario “A Gemelli” IRCCS, from January 2010 to December 2015, and at the General Surgery Operative Unit, San Giovanni di Dio Hospital, Azienda Sanitaria Provinciale Crotone, from January 2016 to June 2020.

All patients provided written consent before the surgical procedures. Preliminary approval to use patient data was obtained from the Institutional Review Board. This study was conducted according to the STROBE guidelines[22].

***Inclusion criteria***

Patients with histologically documented gastric cancer were included in the study. All patients underwent a complete clinical evaluation, including laboratory tests, with complete blood cell count and serum chemistry. In all patients, a preoperative staging of the neoplasm was performed. This included upper digestive endoscopy with biopsy, chest X-ray, liver ultrasound and abdomino-pelvic CT-scan. Tumors were staged according to the latest version of the pathologic classification (pTNM) of the International UICC. The histological classification followed the Lauren criteria[23].

***Exclusion criteria***

Gastric stump and linitis plastica type tumors were excluded from the analysis. Patients with squamous cell cancer or stromal tumors and patients in preoperative neoadjuvant treatment protocols were also excluded from the analysis. Patients with positive surgical resection margins, patients with peritoneal carcinomatosis and/or patients with metastatic disease, and patients with > 1 missing data were not included in the study.

***Surgical rules***

Gastrectomy is defined by the removal of the greater and lesser omentum and perigastric lymph nodes (N1 level, station numbers 1-6). Lymphadenectomy is classified as D2 according to the guidelines of the Japanese Gastric Cancer Association[24]. D2 lymphadenectomy involves the en-bloc removal of lymph node stations 7, 8a and 8p, 9, and 11p and 11d. The left gastric artery was suture ligated at its origin. Lymphadenectomy of the splenic hilum (station 10) was always performed. Hepatoduodenal ligament nodes (station numbers 12a, 12b, 12p) were also dissected. Cholecystectomy was performed in all patients. The resection was extended to the distal esophagus when required by tumor spread and location, which was the case in nearly all of the tumors located at the GEJ. Each lymph node station was removed and classified either during the operation or from the surgical specimen; single lymph nodes were retrieved in the fresh specimen and then submitted to histopathological examination.

For reconstruction, the Roux-en-Y technique was performed in all cases. After total gastrectomy, esophagojejunostomy, using an EEA stapler (diameter 25 mm) was used routinely. In case of a subtotal gastrectomy, Roux-en-Y gastrojejunostomy was performed using an EEA stapler (diameter 25 mm) or a linear stapler (60 mm), at surgeon’s discretion. A trans-anastomotic tube was placed in all patients.

***Pathological data***

The surgical specimens and lymph nodes were assessed by pathologists and were classified according to the 8th Edition of the UICC/AJCC TNM staging system[8]. The T category was used to assess the depth of invasion. For nodal staging, involvement of lymph nodes was defined as follows: N0, no regional lymph nodes metastasis; N1, metastasis in 1 to 2 regional nodes; N2, metastasis in 3 to 6 regional lymph nodes; N3a, metastasis in 7 to 15 regional lymph nodes; N3b, metastasis in > 16 regional lymph nodes. Based on definitive pathological findings, the potentially curative procedures were classified as radical (R0 - microscopic tumor free) or as R1 (microscopic residual disease) according to the absence or presence of residual tumor. Palliative resection was classified based on R2 (macroscopic disease left behind)[24]. Frozen sections were not routinely used in the evaluation of margins, but only in the suspicion of a possible tumor infiltration.

***Postoperative course***

Antibiotic prophylaxis was used in all patients. Low molecular weight heparin treatment was used in all patients for 30 d. All patients were mobilized on the first postoperative day. The bladder catheter was removed on the first postoperative day except in clinical emergencies. The ERAS protocol was not used in any patient. The anastomosis was routinely checked prior to the patient resuming oral intake with a radiological examination using water-soluble contrast on postoperative day 4-7. The trans-anastomotic tube was removed after performing the radiological control if no sign of anastomotic leak was observed. The patients were monitored for 30 d postoperatively for complications and mortality. Complications were considered when occurring within 30 d from surgery, and with a Clavien-Dindo severity grade 2 or more[25]. Anastomotic leakage was defined as a full thickness gastrointestinal defect involving esophagus, anastomosis, staple line, gastric or jejunal stump irrespective of presentation or method of identification; an abscess close to the anastomoses is also considered as anastomotic leakage.

The patients follow up was standardized as follows: clinical examination, full blood tests and dosage of tumor markers, chest X-ray and abdominal ultrasound every 3 mo for the first 2 years and every 6 mo for the following 3 years. Digestive endoscopy and total-body CT scan were performed annually, unless otherwise required. The evaluation of the nutritional status was managed by specialized nutritionists. No patients were lost to follow-up procedure. All patients with positive lymph nodes were treated with systemic adjuvant chemotherapy.

***Statistical analysis***

The clinicopathological characteristics included the patient age, sex, resection type, associated splenectomy, tumor site, histological type, T category, N stage, number of lymph nodes examined, number of metastatic lymph nodes, stage of disease, depth of the primitive tumor and Kattan score. Data are expressed as a mean ± SD. Data were analyzed with standard statistical methods using GraphPad Prism Software (GraphPad, CA, United States). Comparison of means ± SD was performed with the two tailed *t*-test. A univariate analysis with all the demographic data and pathologic factors using the Fisher’s exact test for categorical data and the ANOVA test for continuous data was performed. Subsequently, a multivariate logistic regression was performed. Regardless of the used test, a *P* value < 0.05 was considered statistically significant.

**RESULTS**

During the study period, a total of 304 patients with gastric cancer were treated at the General Surgery Operative Unit, Fondazione Policlinico Universitario “A Gemelli” IRCCS of Rome, and at the General Surgery Operative Unit, San Giovanni di Dio Hospital, Azienda Sanitaria Provinciale of Crotone. Among them, 186 patients (61.2%) underwent a macroscopic potentially curative D2 lymphadenectomy (R0 resection) and were retrospectively analyzed for this observational study. The other 118 patients were excluded from the evaluation for the presence of distant metastases (50 cases, 16.4%), peritoneal carcinosis (44 cases, 14.4%) diagnosed preoperatively either by laparoscopy (31 cases) or by exploratory laparotomy, or due to R2 surgery (24 cases, 7.9%).

***Demographics and intraoperative data***

The main demographic data and clinical characteristics of all patients are reported in Table 1. One hundred and eight patients were male (58.1%) and 78 females (41.9%). The mean age was 64.9 ± 12.4 years (range: 24-90 years). One hundred and six patients were older than 65 years (57.0%) and 80 less than or equal to 65 years (43.0%). The mean tumor size was 4.4 ± 2.3 cm (range 0.5-14 cm). With regards to tumor localization a higher percentage of tumors were in the middle or lower third (31.2% and 43.5%, respectively) of the stomach. As far as UICC/AJCC stage groupings, 95 patients (51.0%) were in early stage of the disease (stage IA, IB, IIA) and 91 patients (49.0%) had advanced disease (stage IIB, IIIA, IIIB, IIIC). Only 40 patients (T1a 36 cases - 19.3%, T1b 4 cases - 2.1%) had early gastric cancer (Table 1). Kattan score was 117.8 ± 45.7 points (range 11-215).

Total gastrectomy was performed in 88 patients (47.3%) and subtotal gastrectomy in 98 (52.7%). Mean age of patients undergoing total gastrectomy was 63 ± 12.1 years and 66.6 ± 12.5 years in those undergoing subtotal gastrectomy (*P* =0.04). In the total gastrectomy patient’s subgroup, the mean Kattan score was 111.3 ± 44.1 points, statistically lower (*P* =0.03) than that observed after subtotal gastrectomy (125.1 ± 46.7 points). The mean tumor size was 4.6 ± 2.6 cm (range 1-14) and 4.1 ± 2.0 cm (range 0.5-11) in patients undergoing total gastrectomy and subtotal gastrectomy, respectively (*P* =0.1).

To obtain an R0 resection, adjacent organs were removed in 5 patients (2.7%): in two cases an atypical liver resection was performed, and in 3 a transverse colon resection was performed. A mean number of 38.3 ± 10.9 lymph nodes (range 17-98) were dissected. The average number of positive lymph nodes was 4.2 ± 6.3 (range 0-39). 74 patients were N0. The mean number of lymph nodes removed was 40 ± 10.4 (range 25-93) and 36.7 ± 11.1 (range 17-98) in total gastrectomy and subtotal gastrectomy, respectively (*P* =0.03). The number of positive lymph nodes was 4.9 ± 6.9 (range 0-39) in patients undergoing total gastrectomy and 3.5 ± 5.7 (range 0-31) in patients undergoing subtotal gastrectomy (*P* =0.1). Lymphadenectomy of the splenic hilum involved splenectomy in 105 cases (56.4%) and was performed with the spleen-preserving technique in the remaining 81 cases (43.6%). 103 patients (55.3%) had > 35 lymph nodes retrieved. Mean duration of surgical procedures was 260 ± 76.1 minutes. Mean length of postoperative hospital stay was 12.7 ± 8.2 d.

***Mortality***

Perioperative mortality rate was 3.8% (7 patients). Causes of death were pancreatic fistula (2 cases), hemoperitoneum (2 cases, one of which was associated with a pancreatic fistula), dehiscence of the esophago-jejunal anastomosis (1 case), dehiscence of the duodenal stump (2 cases) and aspiration pneumonia resulting in ARDS (1 case). A higher mortality was observed in the group of patients aged > 65 years (7 cases out of 80, 8.7%) compared to those aged < 65 years (no cases in 106 patients, *P* =0.002) and in N + patients (7 cases out of 112, 6.2%) compared to N- patients (no cases out of 74 patients, *P* =0.04, Table 2).

In the univariate analysis a significant mortality rate was observed in the group of patients aged > 65 years (*P* =0.008), in patients with Kattan score ≥ 100 points (*P* =0.04), and in patients with advanced gastric cancer (*P* =0.03). Sex (*P* =0.4), type of surgery performed (*P* =0.8), primary tumor location (*P* =0.8), tumor depth (*P* =0.1), and Lauren histological type (*P* =0.4) had no statistically significant influence on perioperative mortality (Table 3). In the multivariate analysis (Table 3) only age > 65 years had a statistically significant influence (T ratio 2.960, *P* =0.004) on perioperative mortality.

***Postoperative overall complications***

Postoperative complications were documented in 40 patients (21.5%). Table 4 Lists the type of complications and their frequency. As shown, pulmonary complications, urinary tract infections, pancreatic fistulas, anastomotic leaks and duodenal fistula were the most frequently observed complications.

A higher incidence of complications was observed in patients undergoing subtotal gastrectomy (29 cases out of 98 patients, 29.5%) compared to those undergoing total gastrectomy (11 cases out of 88 patients, 12.5% - *P* =0.006), in patients with Kattan score ≥ 100 points (32 cases out of 121 patients, 26.4%) compared to those with Kattan score < 100 points (8 out of 65 patients, 12.3% - *P* =0.02) and in those N + (30 out of 112 patients, 26.7%) compared to those N- (10 of 74 patients, 13.5% - *P* =0.04, Table 2).

Univariate analysis (Table 5) confirmed that sex, age, number of lymph nodes harvested, primary tumor site and histological type are not related to morbidity. This is related to the type of surgery (*P* =0.005), the Kattan score (*P* =0.02), the tumor depth (*P* =0.01), T stage (*P* =0.006) and the stage of the disease (*P* =0.01). In the multivariate analysis (Table 5) only the extent of surgery showed a statistically significant correlation (T ratio 2.526, *P* =0.01).

***Postoperative surgical complications***

Surgical complications were observed in 17 patients (9.1%). Among these, the most frequent were duodenal fistula (5 cases), pancreatic fistula (4 cases, one of which associated with hemoperitoneum) and dehiscence of the esophago-jejunal anastomosis. Four patients (2 cases of hemoperitoneum, 2 cases of duodenal fistula) underwent further surgical treatment. The two patients with bowel obstruction underwent adhesion lysis surgery 2 mo and 6 mo after gastric surgery, respectively. All other patients with surgical complications were treated conservatively. A higher incidence of surgical complications was observed in the patient group with more than 35 lymph nodes harvested (16 cases out of 103 patients, 15.5%) compared to patients in which fewer lymph nodes were removed (1 case in 83 patients, 1.2% - *P* =0.0005). Sex (*P* =0.7), age > 65 years (*P* =0.2), type of surgery performed (*P* =0.6), Kattan score (*P* =0.1), lymph node positivity (*P* =0.1) and early stage of disease (*P* =0.5) did not affect the rate of perioperative surgical complications (Table 2).

This was confirmed by the univariate analysis, which documented that the removal of more than 35 lymph nodes (*P* =0.002), the depth of the tumor (*P* =0.04) and the stage of disease (*P* =0.01) are statistically correlated with the development of surgical complications in the postoperative period (Table 6).

On multivariate analysis (Table 6) only one lymphadenectomy with removal of more than 35 lymph nodes correlates significantly with the rate of surgical complications (T ratio 3.222, *P* =0.001).

**DISCUSSION**

Surgical treatment is still the mainstay of curative gastric cancer treatment[4,26-29].For patients who undergo surgery, prognosis is determined by a series of factors, among which depth of invasion, nodal status, and metastasis are the most important. These factors are part of the UICC/AJCC stage formula, which is the most reliable prognostic system. In addition, certain multivariate analyses could identify extent of lymphadenectomy, lymph node ratio (ratio between positive and removed nodes), residual tumors, and grading, as independent prognostic factors. The expected prognosis has great impact on the kind of treatment a patient will receive. The standard for nodal staging of gastric cancer has international variation, and recently significant changes have been made to the AJCC/UICC staging system to simplify lymph node staging in the countries using TNM staging. In the most recent AJCC edition N1 represents 1-6 positive lymph nodes; N2 represents 7-15 positive lymph nodes; and N3 represents > 15 positive lymph nodes. The cut-off points were determined from retrospective databases[30] and in subsequent evaluations showed a superior predictive ability compared to other staging systems[31,32].

The extent of lymphadenectomy is the only factor that can be influenced by the surgeon[33-38]. The total number of lymph nodes resected, or the total number of positive to negative ratio of lymph nodes have all been found to be predictors of survival in gastric cancer patients[37]. For potentially resectable gastric cancer, a linear trend toward superior survival was found for higher lymph node removal up to 35-40 lymph nodes, based on the analysis of the SEER database from 1973 to 1999[38]. Adjuvant therapy is used in advanced gastric cancer to improve the survival and may be useful in high-risk patients treated with limited lymph node dissection. Moreover, lymph node dissection remains crucial to make every effort to improve the prognosis in those patients unsuitable for any adjuvant treatment[39,40]. In a study Biffi *et al*[13] showed that extended lymph node resection offers survival benefit even in the subgroup of patients with early-stage disease. Evaluation of distant disease-free survival risk by number of harvested lymph nodes showed that the risk of recurrence is inversely proportional to the number of dissected lymph nodes. The results did not change when pT1 and pT2-3 cancers were analyzed separately, suggesting the need to remove at least 15 nodes even in patients with early-stage disease[13].

The idea of an extended lymphadenectomy for gastric cancer was first advanced by Mikulicz in 1889, who stated that the distal pancreas should be removed if necessary[40-42]. Recent studies show that D2 lymphadenectomy improves the accuracy of locoregional staging and might reduce disease recurrence in patients with gastric adenocarcinoma[27]. Furthermore, when expert surgeons perform D2 lymphadenectomy and avoid routine distal pancreatectomy and splenectomy, perioperative morbidity and mortality can be kept to a minimum[43,44].

Although neither the 5-year[28] nor 11-year results[40] of the Dutch trial showed a significant improvement in overall survival for patients randomized to D2 lymphadenectomy compared with D1, we believe that surgery remains the only non-standardized therapy in the context of clinical trials and that D2 resection has clinical relevance in most treatment algorithms. Several surgeons agree that standardized D2 lymphadenectomy is an appropriate and potentially beneficial treatment approach[45,46]; like any therapy, surgery must be done safely and correctly by skilled clinicians and should be tailored to the patient and biology of the disease[4,47,48].

Marubini *et al*[10] examined 615 resections, and found no difference in mortality (1.8%) or complication rates (12.8%) with respect to the number of harvested nodes, but better overall survival when more lymph nodes were assessed. With more than 11 years of median follow-up, there was a trend for improved survival for patients with N2 disease who had received a D2 dissection[40]. Another analysis excluding patients with distal pancreatectomy and splenectomy found a survival benefit for the D2 resection patients[49].Clinical series from Asia have found a low rate of nodal recurrences following aggressive lymph nodes dissection. Furthermore, Japanese investigators have recently completed trials of D2 *vs* D2 plus para-aortic nodal dissection, showing better results in small cancer with negative nodes who underwent aggressive D2 dissection[4]. Moreover, if D2 lymphadenectomy was performed, it was likely to have a marked benefit compared to D1 dissection[14,50].

Despite the therapeutic value of lymphadenectomy, mortality and complications are still high in gastric cancer surgery[16,51]. Several studies point out that stomach cancer surgery is a complex procedure that leads to a high risk of morbidity and mortality[15]. Li *et al*[52] observed 30 d and 90 d mortality of 2.0% and 3.4%, respectively, in patients undergoing total gastrectomy for cancer. These data are consistent with what is reported by other authors. Selby *et al*[53] reported data of 2.5% and 2.9% at 30 d and 90 d, respectively, while Pacelli *et al*[54] reported a mortality of 3.5% in 312 patients undergoing potentially curative gastrectomy for cancer. We observed a perioperative mortality rate of 3.8%. A higher mortality was observed in the group of patients aged > 65 years (8.7%) and in N + patients (6.2%).

The risk of postoperative complications is also high. Li *et al*[52] reports a complication rate of 43.9%, with a 14% incidence of severe (class III and class IV according to the Clavien-Dindo classification) complications. A severe complication after total gastrectomy is the anastomotic leak of the esophagojejunal anastomosis. In our experience, dehiscence occurred in 4 patients (2.1%), and was fatal in one case. Selby *et al*[53] and Pacelli *et al*[54] report an incidence of anastomotic dehiscence of 14.7% and 8.6% respectively. In our experience, all anastomotic leakages were identified in the early postoperative period, from day 4 to day 7, by performing routine upper GI contrast studies. The anastomotic leak leads to an increase in the duration of hospitalization, with increases ranging from 13 to 48 d of hospitalization[55]. Another severe complication is duodenal stump dehiscence. This complication occurred in 5 of our patients (2.7%), representing the cause of death in two of them. This complication also increased mortality in the literature[56]. We observed 2 cases of hemoperitoneum (1.0%) and 4 cases of pancreatic fistula (2.1%). These complications were fatal in the two cases of hemoperitoneum and in two of the 4 cases of pancreatic fistula. They were only observed in the patient group where more than 35 lymph nodes had been removed. In our series, mortality occurred only in the group of patients with a higher Kattan score. It seems likely that advanced stage tumors may alter the responsiveness of the patient, increasing the incidence of complications and mortality.

In our study, the overall incidence of surgery-related complications was 9.1%. As easy to predict, morbidity rate is higher in advanced tumors than in the earlier stage. The overall morbidity rate is higher in patients with Kattan score ≥ 100 (*P* =0.02) and in N + patients (*P* =0.04). Contrary to what has been observed in the literature, we documented a higher morbidity rate in patients undergoing subtotal gastrectomy (29 cases *vs* 11 cases after total gastrectomy - *P* =0.006). We believe that this is related to a higher mean age in patients who underwent subtotal gastrectomy (66.6 ± 12.5 years, range: 24-90) than in those who underwent total gastrectomy (63 ± 12.1 years, range: 30-84, *P* =0.04), and a higher mean Kattan score (125.1 ± 46.7 points, range 11-206) than in patients who underwent total gastrectomy (111.3 ± 44.1, range 24-215, *P* =0.03). We observed a higher prevalence, without statistical significance (*P* =0.2), of patients with Kattan ≥ 100 points in the group undergoing subtotal gastrectomy (64 patients, 65.3%) compared to those undergoing total gastrectomy (49 cases, 55.6%). Regarding other parameters considered, such as the size of the tumor (4.1 ± 2.0 cm in subtotal gastrectomy *vs* 4.6 ± 2.6 cm in total gastrectomy, *P* =0.1), the average number of positive lymph nodes (3.5 ± 5.7 in subtotal gastrectomy *vs* 4.6 ± 2.6 in total gastrectomy, *P* =0.1) we did not find statistically significant differences. The number of lymph nodes removed was higher in patients undergoing total gastrectomy (40 ± 10.4) than in those undergoing subtotal (36.7 ± 11.1, *P* =0.03).

A higher incidence of surgical complications was observed in patients in whom more than 35 lymph nodes were removed. This data was confirmed in the univariate and multivariate analyses, where lymphadenectomy with the removal of more than 35 lymph nodes is the only factor that shows correlation with surgical complications. We have documented two cases of hemoperitoneum and 4 pancreatic fistulas, all in patients with spleen-preserving lymphadenectomy. Performing splenectomy for station 10 lymphadenectomy did not in our experience induce an increase in mortality and morbidity. These complications were found to be severe, as reported in the literature[26,57,58]. Many studies show that risk factors for the development of pancreatic fistula are the weight of the patient, the anatomy and texture of the pancreas, intraoperative trauma of the pancreas and the use of high-energy devices when performing lymphadenectomy[26,57].

Although we are aware that the Kattan nomogram was created to evaluate the long-term prognosis and survival of patients with gastric cancer undergoing R0 resection, we observed that the Kattan score, at the cut-off value used, is useful as a prognostic index even in the early postoperative phase. In our experience only patients with Kattan score ≥ 100 points died; a good correlation was also documented as far as the complication rate. Since Kattan takes into account, in addition to age, many characteristics of the tumor and the lymph node status, we have documented, as reported in the literature, that the incidence of mortality and major complications are observed with greater frequency in elderly patients, with more advanced and N + stage cancers. An intrinsic difficulty in using the Kattan score is the fact that the score itself is based on a lot of histopathological information which are not always readily available.

All our patients underwent cholecystectomy. The procedure did not cause biliary complications. This aspect is controversial in the literature. In patients with a radical resection, when a D2 lymphadenectomy is performed and the duodenum is excluded in the intestinal reconstruction, cholecystectomy, considered by some to be a non-essential measure, is necessary to avoid gallstone formation and its complications. In this setting, we believe that prophylactic cholecystectomy is necessary for patients with a good cancer prognosis, as suggested by Pitt and Nakeeb[59]. Studies on the subject conclude that prophylactic cholecystectomy does not have a significant impact on the natural course of the disease[60]. However, it leads to a reduction in the number of biliary complications (which may affect up to 15% of the operated patients) and does not induce an increase in mortality and morbidity rates. In one study, a mortality rate of 1.8% was reported in the case of cholecystectomy performed during an intervention after a gastrectomy. Prophylactic cholecystectomy seems to be unnecessary only in cases where the continuity of the digestive tract involves the use of the duodenum[61]. It was found that the method used to restore intestinal continuity, with preservation of the duodenal transit or excluding the duodenum, is an independent risk factor for both the development of cholelithiasis (*P* =0.018) and cholecystitis and cholangitis (*P* =0.006). It has also been confirmed that in patients who develop cholelithiasis, the incidence of cholecystitis and cholangitis is particularly high when the duodenal transit is excluded (31.3%) compared to those with maintained duodenal transit (7.4%).

**CONCLUSION**

It is fair to reiterate that gastric cancer surgery is a complex surgical procedure. Mortality and postoperative complications are linked both to the extent of gastric demolition and to lymphadenectomy. In our experience, the removal of more than 35 lymph nodes conditioned an increase in surgical complications, although it did not lead to an increase in mortality. Mortality was higher in elderly patients, N + patients and patients with advanced gastric cancer. These parameters (age, T status and N status) are included in the Kattan score, which can be useful, if the histopathological parameters can be obtained quickly, as a prognostic tool even in the early phase.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer surgery is a complex procedure. Lymphadenectomy is essential for the surgical treatment of gastric cancer. Mortality and postoperative morbidity after gastric cancer surgery are not negligible.

***Research motivation***

We investigated in a population of 186 patients with stomach cancer undergoing surgery with D2 lymphadenectomy which factors were related to postoperative mortality and morbidity.

***Research objectives***

To evaluate the factors determining mortality and morbidity in a population of patients undergoing R0 resection and D2 lymphadenectomy for gastric cancer.

***Research methods***

For each patient we calculated the Kattan’s score. The following prognostic variables were assembled for use in validating the nomogram: age, sex, primary site (distal one-third, middle one-third, proximal one-third, and gastroesophageal junction), Lauren histotype (diffuse, intestinal, mixed), number of positive lymph nodes resected, number of negative lymph nodes resected, and depth of invasion as defined by the standard nomenclature.

***Research results***

Perioperative mortality rate was 3.8% (7 patients); a higher mortality rate was observed in patients aged > 65 years (*P* =0.002) and in N+ patients (*P* =0.04). Following univariate analysis, mortality was related to a Kattan’s score ≥ 100 points (*P* =0.04) and the presence of advanced gastric cancer (*P* =0.03). Morbidity rate was 21.0% (40 patients). Surgical complications were observed in 17 patients (9.1%). A higher incidence of morbidity was observed in patients where more than 35 lymph nodes were harvested (*P* =0.0005).

***Research conclusions***

Mortality and morbidity rate are higher in N+ and advanced gastric cancer patients. The removal of more than 35 lymph nodes does not lead to an increase in mortality.

***Research perspectives***

An extended lymph nodes dissection in patients undergoing surgical treatment for gastric cancer is a safe procedure.

**REFERENCES**

1 **Jemal A**, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. *CA Cancer J Clin* 2006; **56**: 106-130 [PMID: 16514137]

2 **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

3 **Songun I**, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010; **11**: 439-449 [PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]

4 **Sasako M**, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 Lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]

5 **Brenkman HJ**, Haverkamp L, Ruurda JP, van Hillegersberg R. Worldwide practice in gastric cancer surgery. *World J Gastroenterol* 2016; **22**: 4041-4048 [PMID: 27099448 DOI: 10.3748/wjg.v22.i15.4041]

6 **Songun I**, van de Velde CJ. How does extended lymphadenectomy influence practical care for patients with gastric cancer? *Nat Clin Pract Oncol* 2009; **6**: 66-67 [PMID: 19092798 DOI: 10.1038/ncponc1300]

7 **Zhu J**, Xue Z, Zhang S, Guo X, Zhai L, Shang S, Zhang Y, Lu H. Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis. *Int J Surg* 2018; **57**: 76-83 [PMID: 30103072 DOI: 10.1016/j.ijsu.2018.08.002]

8 **Amin MB**, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin* 2017; **67**: 93-99 [PMID: 28094848 DOI: 10.3322/caac.21388]

9 **Memon MA**, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-analysis of D1 *vs* D2 gastrectomy for gastric adenocarcinoma. *Ann Surg* 2011; **253**: 900-911 [PMID: 21394009 DOI: 10.1097/SLA.0b013e318212bff6]

10 **Marubini E**, Bozzetti F, Miceli R, Bonfanti G, Gennari L; Gastrointestinal Tumor Study Group. Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. *Eur J Surg Oncol* 2002; **28**: 406-412 [PMID: 12099651]

11 **Chen HN**, Chen XZ, Zhang WH, Chen XL, Yang K, Liu JP, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. Necessity of harvesting at least 25 Lymph nodes in patients with stage N2-N3 resectable gastric cancer: a 10-year, single-institution cohort study. *Medicine (Baltimore)* 2015; **94**: e620 [PMID: 25761190 DOI: 10.1097/MD.0000000000000620]

12 **Asoglu O**, Matlim T, Kurt A, Onder SY, Kunduz E, Karanlik H, Sam B, Kapran Y, Bugra D. Guidelines for extended lymphadenectomy in gastric cancer: a prospective comparative study. *Ann Surg Oncol* 2013; **20**: 218-225 [PMID: 22851047 DOI: 10.1245/s10434-012-2544-7]

13 **Biffi R**, Botteri E, Cenciarelli S, Luca F, Pozzi S, Valvo M, Sonzogni A, Chiappa A, Leal Ghezzi T, Rotmensz N, Bagnardi V, Andreoni B. Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. *Eur J Surg Oncol* 2011; **37**: 305-311 [PMID: 21288685 DOI: 10.1016/j.ejso.2011.01.013]

14 **Liang H**, Deng J. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. *Chin J Cancer Res* 2016; **28**: 397-403 [PMID: 27647967 DOI: 10.21147/j.issn.1000-9604.2016.04.02]

15 **Diers J**, Baum P, Wagner JC, Matthes H, Pietryga S, Baumann N, Uttinger K, Germer CT, Wiegering A. Hospital volume following major surgery for gastric cancer determines in-hospital mortality rate and failure to rescue: a nation-wide study based on German billing data (2009-2017). *Gastric Cancer* 2021; **24**: 959-969 [PMID: 33576929 DOI: 10.1007/s10120-021-01167-8]

16 **Bartlett EK**, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. *Surgery* 2014; **156**: 298-304 [PMID: 24947651 DOI: 10.1016/j.surg.2014.03.022]

17 **Li Z**, Bai B, Zhao Y, Yu D, Lian B, Liu Y, Zhao Q. Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 Lymph node dissection for advanced gastric cancer: A propensity score-matched, case-control study. *Int J Surg* 2018; **54**: 62-69 [PMID: 29698790 DOI: 10.1016/j.ijsu.2018.04.034]

18 **Kim SY**, Kim JH, Chin H, Jun KH. Prediction of postoperative mortality and morbidity in octogenarians with gastric cancer - Comparison of P-POSSUM, O-POSSUM, and E-POSSUM: A retrospective single-center cohort study. *Int J Surg* 2020; **77**: 64-68 [PMID: 32198101 DOI: 10.1016/j.ijsu.2020.03.024]

19 **Shimada Y**. JGCA (The Japan Gastric Cancer Association). Gastric cancer treatment guidelines. *Jpn J Clin Oncol* 2004; **34**: 58 [PMID: 15061149]

20 **Ikeguchi M**, Murakami D, Kanaji S, Ohro S, Maeta Y, Yamaguchi K, Tatebe S, Kondo A, Tsujitani S, Kaibara N. Lymph node metastasis of gastric cancer: comparison of Union International Contra Cancer and Japanese systems. *ANZ J Surg* 2004; **74**: 852-854 [PMID: 15456431 DOI: 10.1111/j.1445-1433.2004.03188.x]

21 **Kattan MW**, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. *J Clin Oncol* 2003; **21**: 3647-3650 [PMID: 14512396 DOI: 10.1200/JCO.2003.01.240]

22 **von Elm E**, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; **370**: 1453-1457 [PMID: 18064739 DOI: 10.1016/S0140-6736(07)61602-X]

23 **Lauren P**. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; **64**: 31-49 [PMID: 14320675 DOI: 10.1111/apm.1965.64.1.31]

24 **Brennan MF**. Current status of surgery for gastric cancer: a review. *Gastric Cancer* 2005; **8**: 64-70 [PMID: 15864711 DOI: 10.1007/s10120-005-0319-6]

25 **Dindo D**, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]

26 **Washio M**, Yamashita K, Niihara M, Hosoda K, Hiki N. Postoperative pancreatic fistula after gastrectomy for gastric cancer. *Ann Gastroenterol Surg* 2020; **4**: 618-627 [PMID: 33319151 DOI: 10.1002/ags3.12398]

27 **Wu CW**, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006; **7**: 309-315 [PMID: 16574546 DOI: 10.1016/S1470-2045(06)70623-4]

28 **Bonenkamp JJ**, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999; **340**: 908-914 [PMID: 10089184 DOI: 10.1056/NEJM199903253401202]

29 **Maruyama K**, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. *Semin Oncol* 1996; **23**: 360-368 [PMID: 8658220]

30 **Roder JD**, Bonenkamp JJ, Craven J, van de Velde CJ, Sasako M, Böttcher K, Stein HJ. Lymphadenectomy for gastric cancer in clinical trials: update. *World J Surg* 1995; **19**: 546-553 [PMID: 7676699]

31 **Ichikura T**, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D, Mochizuki H. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. *Cancer* 1999; **86**: 553-558 [PMID: 10440681 DOI: 10.1002/(sici)1097-0142(19990815)86:4< 553::aid-cncr2> 3.0.co;2-d]

32 **Karpeh MS Jr**, Brennan MF. Gastric carcinoma. *Ann Surg Oncol* 1998; **5**: 650-656 [PMID: 9831115]

33 **D'Ugo D**, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. *Updates Surg* 2020; **72**: 355-378 [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0]

34 **Rausei S**, Galli F, Lianos G, Rosa F, Cossu A, Biondi A, Martignoni F, Cananzi FCM, Fumagalli U, Alfieri S, Persiani R, Quagliuolo V, D'Ugo D, Rosati R. How Should We Measure the Quality of Lymphadenectomy for Gastric Cancer? Anatomical Versus Numerical Criterion. *J Gastrointest Cancer* 2020; **51**: 887-892 [PMID: 31691087 DOI: 10.1007/s12029-019-00321-x]

35 **De Manzoni G**, Baiocchi GL, Framarini M, De Giuli M, D'Ugo D, Marchet A, Nitti D, Marrelli D, Morgagni P, Rinnovati A, Rosati R, Roviello F, Allieta R, Berti S, Bracale U, Capelli P, Cavicchi A, Di Martino N, Donini A, Filippini A, Francioni G, Frascio M, Garofalo A, Giulini SM, Grassi GB, Innocenti P, Martino A, Mazzocconi G, Mazzola L, Montemurro S, Palasciano N, Pantuso G, Pernthaler H, Petri R, Piazza D, Sacco R, Sgroi G, Staudacher C, Testa M, Vallicelli C, Vettoretto N, Zingaretti C, Capussotti L, Morino M, Verdecchia GM. The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer. *Updates Surg* 2014; **66**: 1-6 [PMID: 24523031 DOI: 10.1007/s13304-014-0248-1]

36 **De Manzoni G**, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F, Tomezzoli A, Berselli M, Catalano F, Di Leo A, Framarini M, Giacopuzzi S, Graziosi L, Marchet A, Marini M, Milandri C, Mura G, Orsenigo E, Quagliuolo V, Rausei S, Ricci R, Rosa F, Roviello G, Sansonetti A, Sgroi G, Tiberio GA, Verlato G, Vindigni C, Rosati R, Roviello F. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. *Gastric Cancer* 2017; **20**: 20-30 [PMID: 27255288 DOI: 10.1007/s10120-016-0615-3]

37 **Chen S**, Zhao BW, Li YF, Feng XY, Sun XW, Li W, Zhou ZW, Zhan YQ, Qian CN, Chen YB. The prognostic value of harvested lymph nodes and the metastatic lymph node ratio for gastric cancer patients: results of a study of 1,101 patients. *PLoS One* 2012; **7**: e49424 [PMID: 23166665 DOI: 10.1371/journal.pone.0049424]

38 **Smith DD**, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. *J Clin Oncol* 2005; **23**: 7114-7124 [PMID: 16192595 DOI: 10.1200/JCO.2005.14.621]

39 **Degiuli M**, De Manzoni G, Di Leo A, D'Ugo D, Galasso E, Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M. Gastric cancer: Current status of lymph node dissection. *World J Gastroenterol* 2016; **22**: 2875-2893 [PMID: 26973384 DOI: 10.3748/wjg.v22.i10.2875]

40 **Hartgrink HH**, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004; **22**: 2069-2077 [PMID: 15082726 DOI: 10.1200/JCO.2004.08.026]

41 **Dikken JL**, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. *J Clin Oncol* 2010; **28**: 2430-2436 [PMID: 20368551 DOI: 10.1200/JCO.2009.26.9654]

42 **Hundahl SA**, Peeters KC, Kranenbarg EK, Hartgrink H, van de Velde CJ. Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. *Gastric Cancer* 2007; **10**: 84-86 [PMID: 17577616 DOI: 10.1007/s10120-007-0426-7]

43 **Wu CW**, Chang IS, Lo SS, Hsieh MC, Chen JH, Lui WY, Whang-Peng J. Complications following D3 gastrectomy: post hoc analysis of a randomized trial. *World J Surg* 2006; **30**: 12-16 [PMID: 16369704 DOI: 10.1007/s00268-005-7951-5]

44 **Zhang H**, Liu C, Wu D, Meng Y, Song R, Lu P, Wang S. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. *BMC Cancer* 2010; **10**: 308 [PMID: 20565910 DOI: 10.1186/1471-2407-10-308]

45 **Coccolini F**, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. *World J Gastroenterol* 2016; **22**: 1139-1159 [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139]

46 **Yamashita K**, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N, Kikuchi S, Watanabe M. Trend in gastric cancer: 35 years of surgical experience in Japan. *World J Gastroenterol* 2011; **17**: 3390-3397 [PMID: 21876631 DOI: 10.3748/wjg.v17.i29.3390]

47 **Roggin KK**, Posner MC. D3 or not D3... that is not the question. *Lancet Oncol* 2006; **7**: 279-280 [PMID: 16574543 DOI: 10.1016/S1470-2045(06)70628-3]

48 **Roggin KK**, Hemmerich J, Posner MC. Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? *Lancet Oncol* 2010; **11**: 404-405 [PMID: 20409753 DOI: 10.1016/S1470-2045(10)70098-X]

49 **Hartgrink HH**, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. *J Surg Oncol* 2005; **90**: 153-165 [PMID: 15895448 DOI: 10.1002/jso.20222]

50 **Takeuchi H**, Kitagawa Y. Is lymphadenectomy a predictor or savior for patients with gastric cancer? *Ann Surg Oncol* 2010; **17**: 1257-1258 [PMID: 20140527 DOI: 10.1245/s10434-010-0942-2]

51 **Xiao H**, Xiao Y, Quan H, Liu W, Pan S, Ouyang Y. Intra-abdominal infection after radical gastrectomy for gastric cancer: Incidence, pathogens, risk factors and outcomes. *Int J Surg* 2017; **48**: 195-200 [PMID: 28751223 DOI: 10.1016/j.ijsu.2017.07.081]

52 **Li SS**, Costantino CL, Mullen JT. Morbidity and Mortality of Total Gastrectomy: a Comprehensive Analysis of 90 d Outcomes. *J Gastrointest Surg* 2019; **23**: 1340-1348 [PMID: 31062268 DOI: 10.1007/s11605-019-04228-7]

53 **Selby LV**, Rifkin MB, Yoon SS, Ariyan CE, Strong VE. Decreased length of stay and earlier oral feeding associated with standardized postoperative clinical care for total gastrectomies at a cancer center. *Surgery* 2016; **160**: 607-612 [PMID: 27316826 DOI: 10.1016/j.surg.2016.04.036]

54 **Pacelli F**, Papa V, Rosa F, Tortorelli AP, Sanchez AM, Covino M, Bossola M, Doglietto GB. Four hundred consecutive total gastrectomies for gastric cancer: a single-institution experience. *Arch Surg* 2008; **143**: 769-75; discussion 775 [PMID: 18711037 DOI: 10.1001/archsurg.143.8.769]

55 **Sierzega M**, Choruz R, Pietruszka S, Kulig P, Kolodziejczyk P, Kulig J. Feasibility and outcomes of early oral feeding after total gastrectomy for cancer. *J Gastrointest Surg* 2015; **19**: 473-479 [PMID: 25519083 DOI: 10.1007/s11605-014-2720-0]

56 **Li Z**, Bai B, Ji G, Li J, Zhao Q. Relationship between Clavien-Dindo classification and long-term survival outcomes after curative resection for gastric cancer: A propensity score-matched analysis. *Int J Surg* 2018; **60**: 67-73 [PMID: 30399450 DOI: 10.1016/j.ijsu.2018.10.044]

57 **Hiki N**, Honda M, Etoh T, Yoshida K, Kodera Y, Kakeji Y, Kumamaru H, Miyata H, Yamashita Y, Inomata M, Konno H, Seto Y, Kitano S. Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. *Gastric Cancer* 2018; **21**: 162-170 [PMID: 28887712 DOI: 10.1007/s10120-017-0764-z]

58 **Sano T**, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. *Ann Surg* 2017; **265**: 277-283 [PMID: 27280511 DOI: 10.1097/SLA.0000000000001814]

59 **Pitt HA**, Nakeeb A. Prevention of Gallstone Formation After Gastrectomy. *JAMA Surg* 2020; **155**: 712 [PMID: 32584943 DOI: 10.1001/jamasurg.2020.1527]

60 **Bencini L**, Marchet A, Alfieri S, Rosa F, Verlato G, Marrelli D, Roviello F, Pacelli F, Cristadoro L, Taddei A, Farsi M; Italian Research Group for Gastric Cancer (GIRCG). The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer-a randomized-controlled trial. *Gastric Cancer* 2019; **22**: 632-639 [PMID: 30244294 DOI: 10.1007/s10120-018-0879-x]

61 **Kimura J**, Kunisaki C, Takagawa R, Makino H, Ueda M, Ota M, Oba M, Kosaka T, Akiyama H, Endo I. Is Routine Prophylactic Cholecystectomy Necessary During Gastrectomy for Gastric Cancer? *World J Surg* 2017; **41**: 1047-1053 [PMID: 27896408 DOI: 10.1007/s00268-016-3831-4]

**Footnotes**

**Institutional review board statement:** Not necessary for this type of publication.

**Clinical trial registration statement:** Research Registry ID: researchregistry6939, https://www.researchregistry.com/browse-the-registry#home/.

**Informed consent statement:** Informed consent was waived due to the retrospective nature of this study.

**Conflict-of-interest statement:** No conflict of interest.

**Data sharing statement:** All the data used are present in the text. No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 4, 2021

**First decision:** November 7, 2021

**Article in press:** January 11, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** An T, Rahimi-Movaghar E **S-Editor:** Wang LL **L-Editor:** Filipodia **P-Editor:** Wang LL

**Table 1 Clinico-pathologic patient characteristics**

|  |  |  |
| --- | --- | --- |
| **Characteristics** |  |  |
| Sex |  |  |
| Male | 108 | 58.1% |
| Female | 78 | 41.9% |
| Age, yr | 64.9 ± 12.4 | Range 24-90 |
| Primary tumor location |  |  |
| Gastroesophageal junction | 22 | 11.8% |
| Upper third | 25 | 13.4% |
| Middle third | 58 | 31.2% |
| Lower third | 81 | 43.5% |
| Histological type (Lauren classification) |  |  |
| Enteric type | 96 | 51.6% |
| Diffuse type | 64 | 34.4% |
| Mixed type | 26 | 14.0% |
| Type of resection |  |  |
| Total gastrectomy | 88 |  |
| Subtotal gastrectomy | 98 |  |
| Size, cm | 4.4 ± 2.3 | Range 0.5-14 |
| Number of lymph nodes retrieved | 38.3 ± 10.9 | Range 17-98 |
| Number of positive lymph nodes | 4.1 ± 3.6 | Range 0-39 |
| Operation time, minutes | 260 ± 76.1 |  |
| Length of stay, d | 12.7 ± 8.2 |  |
| T status |  |  |
| T1a | 36 | 19.3% |
| T1b | 4 | 2.1% |
| T2 | 79 | 42.5% |
| T3 | 56 | 30.1% |
| T4a | 2 | 1.1% |
| T4b | 9 | 4.8% |
| Depth |  |  |
| Mucosa | 14 | 7.5% |
| Submucosa | 31 | 16.7% |
| Muscularis propria | 37 | 19.9% |
| Subserosa (suspected invasion) | 46 | 24.7% |
| Subserosa (certain invasion) | 49 | 26.3% |
| Serosa | 4 | 2.1% |
| Adjacent structures | 5 | 2.7% |
| N status |  |  |
| N0 | 74 | 39.8% |
| N1 | 37 | 19.9% |
| N2 | 31 | 16.7% |
| N3a | 33 | 17.7% |
| N3b | 11 | 5.9% |
| Stage AJCC/TNM |  |  |
| IA | 29 | 15.6% |
| IB | 32 | 17.2% |
| IIA | 34 | 18.3% |
| IIB | 35 | 18.8% |
| IIIA | 23 | 12.4% |
| IIIB | 26 | 14.0% |
| IIIC | 7 | 3.8% |

Values are mean ± SD. All the patients were included in all evaluations.

**Table 2 Mortality, overall morbidity and surgical morbidity in all patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **Number of cases** | **Mortality** | **Overall morbidity** | **Surgical morbidity** |
|  | 186 | 7 | 40 | 17 |
| Sex |  |  |  |  |
| Male | 108 | 3 | 24 | 9 |
| Female | 78 | 4 | 16 | 8 |
|  |  | *P* =0.4 | *P* =0.8 | *P* =0.7 |
| Age |  |  |  |  |
| > 65 yr | 80 | 7 | 22 | 10 |
| ≤ 65 yr | 106 | 0 | 18 | 7 |
|  |  | *P* =0.002 | *P* =0.1 | *P* =0.2 |
| Type of surgery |  |  |  |  |
| TG | 88 | 3 | 11 | 7 |
| STG | 98 | 4 | 29 | 10 |
|  |  | *P* =1.0 | *P* =0.006 | *P* =0.6 |
| Kattan score |  |  |  |  |
| ≥ 100 points | 121 | 7 | 32 | 14 |
| < 100 points | 65 | 0 | 8 | 3 |
|  |  | *P* =0.09 | *P* =0.02 | *P* =0.1 |
| Lymphadenectomy |  |  |  |  |
| > 35 lymph nodes | 103 | 3 | 24 | 16 |
| ≤ 35 lymph nodes | 83 | 4 | 16 | 1 |
|  |  | *P* =0.7 | *P* =0.5 | *P* =0.0005 |
| Lymph nodes |  |  |  |  |
| Negative | 74 | 0 | 10 | 4 |
| Positive | 112 | 7 | 30 | 13 |
|  |  | *P* =0.04 | *P* =0.04 | *P* =0.1 |
| T |  |  |  |  |
| Early cancer | 40 | 0 | 5 | 2 |
| Advanced cancer | 146 | 7 | 35 | 15 |
|  |  | *P* =0.3 | *P* =0.1 | *P* =0.5 |
| Splenectomy | 105 | 4 | 24 | 9 |
| Spleen-preserving | 81 | 3 | 16 | 8 |
|  |  | *P* =1.0 | *P* =0.7 | *P* =0.8 |

TG: Total gastrectomy; STG: Subtotal gastrectomy. All the patients were included in all evaluations. Fisher exact test two-tailed.

**Table 3 Univariate and multivariate analysis of variables associated with postoperative mortality**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** |  |  | **Multivariate analysis** |  |
|  | **Number of cases** | **%** | ***P* value** | **T ratio** | ***P* value** |
| Sex (Male) | 3 | 42.9 | 0.406 | 0.5888 | 0.557 |
| Age > 65 yr | 7 | 100 | 0.008 | 2.960 | 0.004 |
| Type of surgery (subtotal gastrectomy) | 4 | 57.1 | 0.810 |  |  |
| Kattan score ≥ 100 | 7 | 100 | 0.048 | 0.9504 | 0.343 |
| Lymph nodes > 35 | 6 | 85.7 | 0.152 | 1.745 | 0.114 |
| Primary site |  |  | 0.821 |  |  |
| Gastroesophageal junction | 1 | 14.3 |  |  |  |
| Upper third | 1 | 14.3 |  |  |  |
| Middle third | 1 | 14.3 |  |  |  |
| Lower third | 4 | 57.1 |  |  |  |
| Depth |  |  | 0.137 | 1.231 | 0.220 |
| Mucosa | 0 |  |  |  |  |
| Submucosa | 1 | 14.3 |  |  |  |
| Muscularis Propria | 0 |  |  |  |  |
| Subserosa (suspected invasion) | 2 | 28.6 |  |  |  |
| Subserosa (certain invasion) | 3 | 42.9 |  |  |  |
| Serosa | 0 |  |  |  |  |
| Adjacent structures | 1 | 14.3 |  |  |  |
| Histological type (Lauren classification) |  |  | 0.436 |  |  |
| Enteric type | 3 | 42.9 |  |  |  |
| Diffuse type | 2 | 28.6 |  |  |  |
| Mixed type | 2 | 28.6 |  |  |  |
| T status |  |  | 0.031 | 1.342 | 0.181 |
| T1a | 0 |  |  |  |  |
| T1b | 0 |  |  |  |  |
| T2 | 3 | 42.9 |  |  |  |
| T3 | 2 | 28.6 |  |  |  |
| T4a | 0 |  |  |  |  |
| T4b | 2 | 28.6 |  |  |  |
| Stage AJCC/TNM |  |  | 0.039 | 0.6371 | 0.525 |
| IA | 0 |  |  |  |  |
| IB | 0 |  |  |  |  |
| IIA | 1 | 14.3 |  |  |  |
| IIB  | 2 | 28.6 |  |  |  |
| IIIA | 1 | 14.3 |  |  |  |
| IIIB | 3 | 42.9 |  |  |  |
| IIIC | 0 |  |  |  |  |

**Table 4 Major postoperative complications with a severity grade 2 or more according Clavien-Dindo classification**

|  |  |  |
| --- | --- | --- |
| **Type of complication** | **Number of cases** | **%** |
| Pulmonary | 12 | 6.4 |
| Urinary tract infection | 10 | 5.4 |
| Leak of esophago-jejunal anastomosis | 4 | 2.1 |
| Intra-abdominal abscess | 1 | 0.5 |
| Abdominal bleeding | 2 | 1.0 |
| Duodenal fistula | 5 | 2.7 |
| Intestinal occlusion | 2 | 1.0 |
| Pancreatic fistula | 4 | 2.1 |

**Table 5 Clinicopathological factors associated with overall morbidity by univariate and multivariate analysis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** |  |  | **Multivariate analysis** |  |
|  | **Number of cases** | **%** | ***P* value** | **T ratio** | ***P* value** |
| Sex (Male) | 24 | 60 | 0.779 | 0.8443 | 0.4 |
| Age > 65 yr | 22 | 55 | 0.575 | 0.4271 | 0.670 |
| Type of surgery (subtotal gastrectomy) | 29 | 72.5 | 0.005 | 2.526 | 0.012 |
| Kattan score ≥ 100 | 32 | 80 | 0.026 | 0.5097 | 0.611 |
| Lymph nodes > 35 | 24 | 60 | 0.962 |  |  |
| Primary site |  |  | 0.180 | 0.3756 | 0.708 |
| Gastroesophageal junction | 5 | 12.5 |  |  |  |
| Upper third | 1 | 2.5 |  |  |  |
| Middle third | 7 | 17.5 |  |  |  |
| Lower third | 27 | 67.5 |  |  |  |
| Depth |  |  | 0.017 | 0.2270 | 0.821 |
| Mucosa | 1 | 2.5 |  |  |  |
| Submucosa | 5 | 12.5 |  |  |  |
| Muscularis propria | 5 | 12.5 |  |  |  |
| Subserosa (suspected invasion) | 11 | 27.5 |  |  |  |
| Serosa | 3 | 7.5 |  |  |  |
| Adjacent structures | 4 | 10.0 |  |  |  |
| Histological type (Lauren classification) |  |  | 0.265 | 0.4180 | 0.677 |
| Enteric | 17 | 42.5 |  |  |  |
| Diffuse | 13 | 32.5 |  |  |  |
| Mixed | 10 | 25.0 |  |  |  |
| T status |  |  | 0.006 | 0.6177 | 0.538 |
| 1a | 0 |  |  |  |  |
| 1b | 5 | 12.5 |  |  |  |
| 2 | 15 | 37.5 |  |  |  |
| 3 | 12 | 30.0 |  |  |  |
| 4a | 4 | 10.0 |  |  |  |
| 4b | 4 | 10.0 |  |  |  |
| Stage AJCC/TNM |  |  | 0.018 | 0.8390 | 0.403 |
| IA | 5 | 12.5 |  |  |  |
| IB | 2 | 5.0 |  |  |  |
| IIA | 6 | 15.0 |  |  |  |
| IIB | 10 | 25.0 |  |  |  |
| IIIA | 7 | 17.5 |  |  |  |
| IIIB | 8 | 20.0 |  |  |  |
| IIIC | 2 | 5.0 |  |  |  |

AJCC: American Joint Committee on Cancer.

**Table 6 Factors associated with surgical complications in univariate and multivariate analysis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** |  |  | **Multivariate analysis** |  |
|  | **Number of cases** | **%** | ***P* value** | **T ratio** | ***P* value** |
| Male sex | 9 | 52.9 | 0.653 | 0.4193 | 0.675 |
| Age > 65 yr | 10 | 58.8 | 0.502 | 1.192 | 0.235 |
| Type of surgery (subtotal gastrectomy) | 10 | 58.8 | 0.595 |  |  |
| Kattan score ≥ 100 | 14 | 82.3 | 0.116 | 0.08543 | 0.932 |
| Lymph nodes > 35 | 16 | 94.1 | 0.002 | 3.222 | 0.001 |
| Primary site |  |  | 0.609 |  |  |
| Gastroesophageal junction | 4 | 23.5 |  |  |  |
| Upper third | 1 | 5.9 |  |  |  |
| Middle third | 2 | 11.8 |  |  |  |
| Lower third | 10 | 58.8 |  |  |  |
| Depth |  |  | 0.045 | 0.8208 | 0.413 |
| Mucosa | 0 |  |  |  |  |
| Submucosa | 2 | 11.8 |  |  |  |
| Muscularis Propria | 2 | 11.8 |  |  |  |
| Subserosa (suspected invasion) | 5 | 29.4 |  |  |  |
| Subserosa (certain invasion) | 3 | 17.6 |  |  |  |
| Serosa | 2 | 11.8 |  |  |  |
| Adjacent structures | 3 | 17.6 |  |  |  |
| Histological type (Lauren classification) |  |  | 0.817 |  |  |
| Enteric type | 8 | 47.1 |  |  |  |
| Diffuse type | 4 | 23.5 |  |  |  |
| Mixed type | 5 | 29.4 |  |  |  |
| T status |  |  | 0.054 | 1.102 | 0.272 |
| T1a | 0 |  |  |  |  |
| T1b | 2 | 11.8 |  |  |  |
| T2 | 7 | 41.2 |  |  |  |
| T3 | 4 | 23.5 |  |  |  |
| T4a | 1 | 5.9 |  |  |  |
| T4b | 3 | 17.6 |  |  |  |
| Stage AJCC/TNM |  |  | 0.019 | 0.8237 | 0.411 |
| IA | 1 | 5.9 |  |  |  |
| IB | 0 |  |  |  |  |
| IIA | 3 | 17.6 |  |  |  |
| IIB  | 5 | 29.4 |  |  |  |
| IIIA | 3 | 17.6 |  |  |  |
| IIIB | 4 | 23.5 |  |  |  |
| IIIC | 1 | 5.9 |  |  |  |

AJCC: American Joint Committee on Cancer.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**